Abpro Holdings, Inc. (ABP)
NASDAQ: ABP · Real-Time Price · USD
5.81
-0.56 (-8.79%)
At close: Dec 5, 2025, 4:00 PM EST
5.87
+0.06 (1.03%)
After-hours: Dec 5, 2025, 7:29 PM EST
Abpro Holdings Employees
As of December 31, 2024, Abpro Holdings had 15 total employees, including 6 full-time and 9 part-time employees. The number of employees decreased by 27 or -64.29% compared to the previous year.
Employees
15
Change
-27
Growth
-64.29%
Revenue / Employee
n/a
Profits / Employee
-$1,469,333
Market Cap
15.78M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15 | -27 | -64.29% |
| Dec 31, 2017 | 42 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ABP News
- 4 weeks ago - Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager - GlobeNewsWire
- 4 weeks ago - Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 - GlobeNewsWire
- 7 months ago - Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager - GlobeNewsWire
- 9 months ago - Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - GlobeNewsWire
- 9 months ago - Abpro Statement on the Departure of Former CEO Ian Chan - GlobeNewsWire
- 1 year ago - Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing - GlobeNewsWire